他汀类药物治疗脓毒症作用机制的研究进展
-
摘要: 正脓毒症是具有感染依据的全身炎症反应综合征,是严重创(烧)伤、休克、大手术后等临床危重症患者的严重并发症之一,并可进一步发展为脓毒性休克和多器官功能障碍综合征(MODS),是临床危重病症患者死亡的重要原因之一[1]。目前除重组人活化蛋白C外,尚无理想的能够减轻脓毒症炎症反应并改善其预后的新疗法。他汀类药物是羟甲基戊二酸辅酶A还原酶抑制剂,可干扰胆固醇代谢,是目前广泛应用的降血脂药物。而近年来越来越多的研究[2-3]显示,他汀类药物还能改善脓毒症模型和患者的预后。本文就他汀类药物抗脓毒症的可能作用机制作一综述。
-
[1] 《一氧化氮合酶对早期内毒素休克猕猴肾脏的影响》[J].中国危重病急救医学,2006(7). [2] [2] Falagas ME,Makris GC,Matthaiou DK,et al.Statins for infection and sepsis:a systematic review of the clinical evidence[J].Antimicrob Chemoth,2008,61(4):774-785. [4] [3] Mzayek F,Ylstalo J,Krogstad DJ.Apoptosis of endothelial cells in bacterial sepsis and severe Plasmodium falciparum malaria:do we know enough to consider clinical trials[J].Crit Care Med,2008,36(9):2690-2692. [6] [4] Fraunberger P,Drexel H,Walli AK.Pathophysiology of sepsis and possible influence of statins[J].Dtsch Med Wochenschr,2010,135(43):2128-2132. [5] Ando H,Takamura T,Ota T,et al.Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis[J].Pharmacol Exp Ther,2000,294(3):1043-1046. [9] [6] Freitas A,Alves-Filho JC,Victoni T,et al.IL-17receptor signaling is required to control polymicrobial sepsis[J].Immunology,2009,182(12):7846-7854. [11] [7] 呙勇.脓毒症大鼠脾脏中IL-17、IL-17R的表达及乌司他丁注射液的干预作用[D].长沙:中南大学湘雅医院,2009. [13] [8] Mason JC,Ahmed Z,Mankof R,et al.Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury[J].Circ Res,2002,91(8):696-703. [15] [9] Yoshida M,Sawada T,Ishii H,et al.HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro:involvement of Rho GTPase-dependent mechanism[J].Arterioscler Thromb Vasc Biol,2001,21(7):1165-1171. [17] [10] Pruefer D,Makowski J,Schnell M,et al.Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin[J].Circulation,2002,106(16):2104-2110. [19] [11] Veillard NR,Braunersreuther V,Arnaud C,et al.Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages[J].AtheroscIerosis,2006,188(1):51-58. [21] [12] Montecucco F,Burger F,Pelli G,et al.Statins inhibit C-reactive protein-induced chemokine secretion,ICAM-1upregulation and chemotaxis in adherent human monocytes[J].Rheumatology(Oxford),2009,48(3):233-242. [23] [13] Marius T,Yaniv A,Robert SR,et al.Statins and sepsis:multiple modifications at multiple levels[J].Lancet Infect Dis,2007,7(5):358-368. [14] Zhang J,Cheng X,Liao YH,et al.Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction[J].Cardiovase Drugs Ther,2005,19(1):13-21. [26] [15] Jacobson JR,Barnard JW,Grigoryev DN,et al.Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury[J].Am J Physiol Lung Cell Mol Physiol,2005,288(6):L1026-L1032. [28] [16] Gonzlez D,Herrera B,Beltrn A,et al.Nitric oxide disrupts VE-cadherin complex in murine microvascular endothelial cells[J].Biochern Biophys Res Communn,2003,304(1):113-118. [30] [17] Scalia R,Stalker TJ.Microcirculation as a target for the anti-inflammatory properties of statins[J].Microcirculation,2002,9(6):431-442. [18] Waldow T,Witt W,Weber E,et al.Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and NFkappaB activation in endothelial cells[J].Nitric Oxide,2006,15(2):103-113. [33] [19] Mastuda N,Hayashi Y,Takahashi Y,et al.Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric ateries from septic rabbits depending on the altered phosphatidylinositol3-kinase/Akt pathway:Reversal effect of fluvastatin therapy[J].Pharmacol Exp Ther,2006,319(3):1348-1354. [35] [20] Cybulsky MI,Chan MK,Movat HZ.Acute inflammation and microthrombosis induced by endotoxin,interleukin-1,and tumor or necrosis faeor and their implication in gram-negative infection[J].Lab Invest,1998,58(4):365-378. [37] [21] Mutunga M,Fulton B,Bullock R,et al.Circulating endothelial cell in patients with septic shock[J].Am J Respir Crit Care Med,2001,163(1):195-200. [39] [22] Bannerman DD,Goldblum SE.Mechanisms of bacterial lipopo-lysaccharide-induced endothelial apoptosis[J].Am J Physiol Lung Cell Mol Physiol,2003,284(6):L899-L914. [41] [23] Niessner A,Steiner S,Speidl WS,et al.Simvastatin suppresses endotoxin-induced up regulation of toll-like receptors4and2in vivo[J].Atherosclerosis,2006,189(2):408-413. [43] [24] 任珊.辛伐他汀预处理对脓毒症大鼠凝血功能及肝脏C反应蛋白的影响[D].石家庄:河北医科大学,2010. [45] [25] Palinski W,Napoli C.Unraveling pleiotropic effects of statins on plaque rupture[J].Arterioscler Thromb Vasc Riol,2002,22(11):1745-1750. [26] Gao F,Linhartova L,Johnston AM,et al.Statins and sepsis[J].Br J Anaesth,2008,100(3):288-298. [48] [27] Steiner S,Speidl WS,Pleiner P,et al.Simvastatin blunts endotoxin induced tissue factor in vivo[J].Circulation,2005,11(14):1841-1846. [28] Beltowski J.Statins and modulation of oxidative stress[J].Toxicol Mech Methods,2005,15(2):61-92. [51] [29] Border JR,Hassett J,LaDuca J,et al.The gut origin septic states in blunt multiple trauma(ISS=40)in the ICU[J].Ann Surq,1987,206(4):427-428. [30] 《他汀类药物治疗脓毒症作用机制研究进展》[J].浙江医学,2009(7). [54] [31] 《脓毒症大鼠肺血管内皮细胞、细胞间粘附分子1和E-选择素的变化及其意义》[J].中国免疫学杂志,2009(11). [56] [32] 《脓毒症免疫调理治疗研究进展》[J].解放军医学杂志,2010(6). [58] [33] 《他汀类调脂药对脓毒症患者的保护作用》[J].医学与哲学:临床决策论坛版,2010(6). [60] [34] 《国产瑞舒伐他汀对血脂及炎症因子影响的临床研究》[J].当代医学,2011(3).
点击查看大图
计量
- 文章访问数: 3858
- HTML全文浏览量: 768
- PDF下载量: 431
- 被引次数: 0